La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Legend Biotech Gestione

Gestione criteri di controllo 2/4

Legend Biotech's Il CEO è Ying Huang, nominato in Sep2020, ha un mandato di 3.92 anni. possiede direttamente 0.035% delle azioni della società, per un valore di $ 3.65M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 3.2 anni.

Informazioni chiave

Ying Huang

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4.1yrs
Proprietà del CEO	0.03%
Durata media del management	2.4yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30

AMMINISTRATORE DELEGATO

Ying Huang (51 yo)

4.1yrs

Mandato

Dr. Ying Huang, Ph D., had been Chief Financial Officer of Legend Biotech Corporation since July 2019 until May 09, 2022 and was its Interim Chief Executive Officer since September 21, 2020 until November...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ying Huang	CEO & Director	4.1yrs	Nessun dato	0.035% $ 2.8m
Lori Macomber	Chief Financial Officer	2.4yrs	Nessun dato	0.0031% $ 241.0k
Doug Wallace	Vice President of Global Operations	less than a year	Nessun dato	Nessun dato
Guowei Fang	Chief Scientific Officer & Head of Business Development	no data	Nessun dato	Nessun dato
Joanne Choi	Senior Manager of Investor Relations	no data	Nessun dato	Nessun dato
James Pepin	General Counsel	less than a year	Nessun dato	Nessun dato
Tim Roberts	Global Compliance Officer	less than a year	Nessun dato	Nessun dato
Deborah Wong	Executive Director of Strategic Marketing & Corporate Communications	no data	Nessun dato	Nessun dato
Elaine Qian	VP & Global Head of Human Resources	1.5yrs	Nessun dato	Nessun dato
Yuhong Qiu	Senior Vice President of Global Regulatory Affairs	2.8yrs	Nessun dato	Nessun dato
Steven Gavel	Senior Vice President of Commercial Development	2.8yrs	Nessun dato	Nessun dato
Alan Kick	Senior Vice President of Global Quality	2.8yrs	Nessun dato	Nessun dato

2.4yrs

Durata media

Gestione esperta: Il team dirigenziale di LEGN è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ying Huang	CEO & Director	2.8yrs	Nessun dato	0.035% $ 2.8m
John M. Maraganore	Member of Strategic Advisory Board	1.5yrs	Nessun dato	Nessun dato
Li Zhu	Non-Independent Director	3.9yrs	Nessun dato	Nessun dato
Corazon Sanders	Independent Director	4.4yrs	Nessun dato	0.010% $ 823.2k
Xiaohui Ji	Independent Director	4.4yrs	Nessun dato	0.0050% $ 395.0k
Tomas Heyman	Independent Director	2.2yrs	Nessun dato	0.0011% $ 86.9k
Fangliang Zhang	Independent Chairman	2.2yrs	Nessun dato	0% $ 0
Ye Wang	Director	9.4yrs	Nessun dato	0% $ 0
Michel Vounatsos	Member of Strategic Advisory Board	1.5yrs	Nessun dato	Nessun dato
Wai Man Yau	Independent Director	4.4yrs	Nessun dato	0.0010% $ 80.6k
Patrick Casey	Independent Director	3.8yrs	Nessun dato	0.0069% $ 542.8k
Li Mao	Independent Director	2.2yrs	Nessun dato	0.0019% $ 148.5k

3.3yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LEGN sono considerati esperti (durata media dell'incarico 3.2 anni).

Legend Biotech Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Recent updates

Consensus EPS estimates fall by 14%, revenue upgraded

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Chief Financial Officer notifies of intention to sell stock

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients

Consensus estimates of losses per share improve by 33%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech Corporation Announces Positive Overall Survival Results of Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Legend Biotech: Solid Traction With Carvykti Rollout

Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel)

Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel)

Price target increased by 7.7% to US$79.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million.

Chief Financial Officer notifies of intention to sell stock

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: Revenues miss analyst expectations

Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021)

Legend Biotech Corporation Announces Research and Development Update

Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

High number of new and inexperienced directors

Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation Elects Philip Yau as Director

Consensus forecasts updated

Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Legend Biotech Corporation Announces Board Changes

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Legend Biotech stock slides on proposed ADS offering